MCKESSON CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 535.4 USD | +0.64% |
|
+1.81% | +15.65% |
Financials (USD)
| Sales 2024 * | 312B | Sales 2025 * | 338B | Capitalization | 69.91B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.03B | Net income 2025 * | 3.52B | EV / Sales 2024 * | 0.23 x |
| Net Debt 2024 * | 1.78B | Net Debt 2025 * | 375M | EV / Sales 2025 * | 0.21 x |
| P/E ratio 2024 * |
24.3
x | P/E ratio 2025 * |
19.4
x | Employees | 48,000 |
| Yield 2024 * |
0.45% | Yield 2025 * |
0.5% | Free-Float | 46.58% |
More Fundamentals
* Assessed data
More news
Latest transcript on McKesson Corporation
More recommendations
More press releases
| 1 day | +0.64% | ||
| 1 week | +1.34% | ||
| Current month | -0.27% | ||
| 1 month | +0.54% | ||
| 3 months | +10.31% | ||
| 6 months | +18.98% | ||
| Current year | +15.65% |
1 week
514.88
537.15
1 month
514.88543.00
Current year
462.70543.00
1 year
352.34543.00
3 years
180.42543.00
5 years
112.60543.00
10 years
106.11543.00
| Managers | Title | Age | Since |
|---|---|---|---|
Brian Tyler
CEO | Chief Executive Officer | 57 | 11-12-31 |
| Director of Finance/CFO | 55 | 18-01-26 | |
Francisco Fraga
CTO | Chief Tech/Sci/R&D Officer | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donald Knauss
CHM | Chairman | 73 | 14-10-19 |
Webster Dunbar
BRD | Director/Board Member | 62 | 22-03-31 |
| Director/Board Member | 66 | 22-01-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.31% | 1,026 M€ | +6.20% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 535.4 | +0.64% | 583,455 |
| 24-04-23 | 532 | +0.89% | 490,789 |
| 24-04-22 | 527.3 | +0.47% | 893,497 |
| 24-04-19 | 524.8 | +1.16% | 645,525 |
| 24-04-18 | 518.8 | -1.35% | 631,442 |
Delayed Quote Nyse, April 24, 2024 at 04:00 pm EDT
More quotes
McKesson Corporation specializes in pharmaceutical product distribution. The group also offers technological services to healthcare companies. Net sales break down by activity as follows:
- distribution of pharmaceutical products (87%);
- distribution of medical and surgical products (4%);
- other (1.6%): primarily technology services and software sales.
The remaining net sales (7.4%) are from international activities.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Q4 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
532
USD
Average target price
559.5
USD
Spread / Average Target
+5.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.65% | 69.91B | |
| +2.72% | 25.14B | |
| +5.62% | 8.32B | |
| +6.10% | 8.07B | |
| -21.85% | 7.97B | |
| +0.73% | 4.56B | |
| +17.40% | 4.31B | |
| -0.14% | 3.99B | |
| -2.34% | 3.87B | |
| +21.03% | 3.63B |
- Stock Market
- Equities
- MCK Stock
